The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 360:2474-2475 June 4, 2009 Number 23
NextNext

Warfarin Pharmacogenetics

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by The International Warfarin Pharmacogenetics Consortium
-PubMed Citation
To the Editor: The study of a pharmacogenetic algorithm for estimating the appropriate initial dose of warfarin, reported by the International Warfarin Pharmacogenetics Consortium (Feb. 19 issue),1 highlights the challenges in fashioning a generally applicable algorithm for warfarin dosing. The authors used an imprecise end point — namely, the dose predicted to achieve a stable international normalized ratio (INR). The investigators conclude that their model would be most helpful in the case of patients for whom the stable, therapeutic warfarin dose is less than 22 mg or more than 48 mg per week, but would be less useful for patients . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.